Nevirapine or Atazanavir/Ritonavir Given With Emtricitabine/Tenofovir in Human Immunodeficiency Virus (HIV)-1-infected Treatment Naive Adults

This study has been completed.

Sponsor:

Information provided by (Responsible Party):

Boehringer Ingelheim Pharmaceuticals

ClinicalTrials.gov Identifier:

NCT00389207

First received: October 17, 2006

Last updated: May 18, 2012

Last verified: May 2012

History of Changes

Results First Received: January 13, 2012

Study Type:	Interventional
Study Design:	Allocation: Randomized; Endpoint Classification: Safety/Efficacy Study; Intervention Model: Parallel Assignment; Masking: Open Label; Primary Purpose: Treatment
Condition:	HIV Infections
Interventions:	Drug: nevirapine bid Drug: nevirapine qd Drug: atazanavir

Participant Flow

Show Participant Flow

Baseline Characteristics

Hide Baseline Characteristics

Reporting Groups

	Description
Nevirapine QD	Nevirapine (NVP) 400mg QD on a background of the fixed combination Truvada® (emitricitabine 200mg QD and tenofovir 300mg QD)
Nevirapine BID	NVP 200mg BID on a background of the fixed combination Truvada®
Atazanvir/Ritonavir	ATZ/r on a background of the fixed combination Truvada®
Total	Total of all reporting groups

Baseline Measures

	Nevirapine QD	Nevirapine BID	Atazanvir/Ritonavir	Total
Number of Participants [units: participants]	188	188	193	569
Age [units: years] Mean ± Standard Deviation	38.4 ± 9.7	40.0 ± 10.5	37.6 ± 9.5	38.6 ± 9.9
Gender [units: participants]
Female	36	25	31	92
Male	152	163	162	477
Baseline HIV viral load category [units: participants]
Baseline HIV viral load ≤ 100,000 copies/mL	71	71	65	207
Baseline HIV viral load > 100,000 copies/mL	117	117	128	362
Baseline log10 HIV viral load ^[1] [units: log 10 Copies/mL] Mean ± Standard Deviation	5.1 ± 0.7	5.1 ± 0.6	5.1 ± 0.7	5.1 ± 0.7
Baseline CD4+ cell count ^[1] [units: Cells/mm^3] Mean ± Standard Deviation	183.3 ± 95.5	202.9 ± 93.6	193.2 ± 95.8	193.2 ± 95.1

[1]	185 NVP QD patients, 188 NVP BID patients and 192 ATZ/R patients had data

Outcome Measures

Show All Outcome Measures

1. Primary:

Treatment Response at Week 48 [ Time Frame: From baseline to Week 48 ]

Show Outcome Measure 1

2. Secondary:

Treatment Response at Week 48 (TLOVR Algorithm) [ Time Frame: From baseline to Week 48 ]

Show Outcome Measure 2

3. Secondary:

Proportion of Patients With VL < 50 Copies/ml [ Time Frame: From baseline to Weeks 4, 8, 12, 24, 36, 48, 60, 72, 84, 96, 108, 120, 132 and 144/EOT ]

Show Outcome Measure 3

4. Secondary:

Proportion of Patients With VL < 400 Copies/ml [ Time Frame: From baseline to Weeks 4, 8, 12, 24, 36, 48, 60, 72, 84, 96, 108, 120, 132 and 144/EOT ]

Show Outcome Measure 4

5. Secondary:

Change in CD4+ Count From Baseline [ Time Frame: From baseline to Weeks 4, 8, 12, 24, 36, 48, 60, 72, 84, 96, 108, 120, 132 and 144/EOT ]

Show Outcome Measure 5

6. Secondary:

Change in Framingham Score From Baseline [ Time Frame: From baseline to Weeks 48, 96 and 144/EOT ]

Show Outcome Measure 6

7. Secondary:

Change in Mental Health Summary (MHS) Score From Baseline [ Time Frame: From baseline to Weeks 48, 96 and 144/EOT ]

Show Outcome Measure 7

8. Secondary:

Change in Physical Health Summary (PHS) Score From Baseline [ Time Frame: From baseline to Weeks 48, 96 and 144/EOT ]

Show Outcome Measure 8

9. Secondary:

Number of Patients Hospitalized [ Time Frame: From baseline to Week 24, Week 24 to 48, Week 48 to 96, and Week 96 to 144/EOT ]

Show Outcome Measure 9

10. Secondary:

Non-scheduled Physician Visits [ Time Frame: From baseline to Week 24, Week 24 to 48, Week 48 to 96, and Week 96 to 144/EOT ]

Show Outcome Measure 10

11. Secondary:

Genotypic Resistance Associated With Virologic Failure [ Time Frame: From baseline to Week 48 ]

Show Outcome Measure 11

12. Secondary:

Treatment-emergent AIDS-defining Illness [ Time Frame: From baseline to Week 144 ]

Show Outcome Measure 12

13. Secondary:

Treatment-emergent AIDS-defining Illness Leading to Death [ Time Frame: From baseline to Week 144 ]

Show Outcome Measure 13

14. Secondary:

Lipodystrophy [ Time Frame: From baseline to Week 144 ]

Show Outcome Measure 14

15. Secondary:

Serum Lipid Abnormalities [ Time Frame: From baseline to Week 144 ]

Show Outcome Measure 15

16. Secondary:

Glycaemic Abnormalities [ Time Frame: From baseline to Week 144 ]

Show Outcome Measure 16

Serious Adverse Events

Show Serious Adverse Events

Other Adverse Events

Show Other Adverse Events

More Information

Hide More Information

Certain Agreements:

Principal Investigators are NOT employed by the organization sponsoring the study.

There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.

The agreement is:

	The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.
	The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.
	Other disclosure agreement that restricts the right of the PI to discuss or publish trial results after the trial is completed. Restriction Description: Other - Any publication of the result of this trial must be consistent with the Boehringer Ingelheim publication policy. The rights of the investigator and of the sponsor with regard to publication of the results of this trial are described in the investigator contract.

Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.

Results Point of Contact:

Name/Title: Boehringer Ingelheim Call Center
Organization: Boehringer Ingelheim Pharmaceuticals
phone: 1-800-243-0127
e-mail: clintriage.rdg@boehringer-ingelheim.com

No publications provided by Boehringer Ingelheim Pharmaceuticals

Publications automatically indexed to this study:

Seclén E, Soriano V, González MM, Martín-Carbonero L, Gellermann H, Distel M, Kadus W, Poveda E. Impact of baseline HIV-1 tropism on viral response and CD4 cell count gains in HIV-infected patients receiving first-line antiretroviral therapy. J Infect Dis. 2011 Jul;204(1):139-44.

Soriano V, Arastéh K, Migrone H, Lutz T, Opravil M, Andrade-Villanueva J, Antunes F, Di Perri G, Podzamczer D, Taylor S, Domingo P, Gellermann H, de Rossi L; ARTEN investigators. Nevirapine versus atazanavir/ritonavir, each combined with tenofovir disoproxil fumarate/emtricitabine, in antiretroviral-naive HIV-1 patients: the ARTEN Trial. Antivir Ther. 2011;16(3):339-48.

Responsible Party:	Boehringer Ingelheim Pharmaceuticals
ClinicalTrials.gov Identifier:	NCT00389207 History of Changes
Other Study ID Numbers:	1100.1470, 2005-004330-40
Study First Received:	October 17, 2006
Results First Received:	January 13, 2012
Last Updated:	May 18, 2012
Health Authority:	Argentina: A.N.M.A.T. (Administracion Nacional de Medicamentos, Alimentos y Tecnologia Medica) Germany: Federal Institute for Drugs and Medical Devices Great Britain: MHRA Italy: Comitato Etico dell'Azienda Osp. Riuniti di Bergamo - Bergamo Mexico: Comision Federal para la Proteccion contra Riesgos Sanitarios (COFEPRIS) Poland: Office for Registration of Medicinal Products, Medical Devices and Biocidal Products Portugal: National Pharmacy and Medicines Institute Romania: National Medicines Agency, Bucharest Spain: Agencia Espanola del Medicamento y Productos Sanitarios Switzerland: Swissmedic Schweizerisches Heilmittelinstitut (Swiss Agency for Therapeutic Products)

To Top